| Document |
Document Title |
|
WO/2022/153003A1 |
The present invention relates to the field of perfumes and flavourings. More particularly, it relates to valencene derivatives and the use thereof as a perfuming or flavouring agent. It also relates to a perfuming or flavouring compositi...
|
|
WO/2015/136292A9 |
The invention relates to a DDX3X inhibitorfor use in the treatment of pneumovirus infection in a mammal, wherein the DDX3X inhibitor may be a compound of Formula (I) wherein y, Z, R1, X, L, Ra and Rb are as defined herein. The invention ...
|
|
WO/2022/065802A1 |
A polythiol composition according to exemplified embodiments comprises a first polythiol compound, and a second polythiol compound having a larger molecular weight than the first polythiol compound and having a number of functional group...
|
|
WO/2022/029358A1 |
The present invention relates to a compound 1 or 2 or a composition comprising same. The invention also relates to a method for obtaining compound 1 or 2, and to the use of the compounds to detect GHB in beverages. The invention also inc...
|
|
WO/2021/255279A1 |
The invention relates to novel compounds of formulae (I') and (II') for the treatment, alleviation or prevention of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a compone...
|
|
WO/2021/175822A1 |
Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and/or N-oxides of those compounds, can be used as pesticides.
|
|
WO/2021/165187A1 |
The invention relates to a process for preparing 2-(phenylimino)-3-alkyl-1,3-thiazolidin-4-ones of the general formula (I), wherein Y1, Y2, R1, R2 and R3 have the meanings indicated in the description.
|
|
WO/2021/162096A1 |
The present invention relates to a method for producing 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-metho
xy-N-methylquinoline-6-carboxamide, the method comprising a step for linking 4-(4-amino-2-fluorophenoxy)-7-methoxy-N-met...
|
|
WO/2021/162097A1 |
The present invention relates to: 4-hydroxy-7-methoxy-N-methylquinoline-6-carboxamide, 7-methoxy-N-methy-4-(4-(3-(2-phenylacetyl)thioureido)phenoxy
)quinoline-6-carboxamide, 4-(2-fluoro-4-(2-phenylacetamide)phenoxy)-7-methoxy-N-methyl
qu...
|
|
WO/2021/136431A1 |
Disclosed is a series of benzo[d][1,2,3]triazole ether compounds, and specifically disclosed are a compound shown in formula (I) and pharmaceutically acceptable salts thereof.
|
|
WO/2021/107478A1 |
The present invention relates to a method for preparing 1-(4-benzyloxy-benzyl)-3-methyl-thiourea and a method for preparing a novel stable crystalline form A of 1-(4-benzyloxy-benzyl)-3-methyl-thiourea.
|
|
WO/2021/107476A1 |
The present invention relates to a 1-(4-benzyloxy-benzyl)-3-methyl-thiourea compound in crystalline forms A, B, C, or amorphous form, a method for preparing the compound in the crystalline or amorphous forms, and a use of the compound fo...
|
|
WO/2021/102266A1 |
Di alkenyl succinic amide acids and processes for making and using same. The di alkenyl succinic amide acid can have a chemical formula of (I): where R1 and R2 can independently be a linear or branched C8 to C24 alkenyl group, Z1, Z2, Z3...
|
|
WO/2021/073131A1 |
Provided in the present invention are a medicament for effectively killing drug-resistant disease bacteria and an application thereof in inhibiting drug-resistant disease bacteria. Specifically, provided in the present invention is a com...
|
|
WO/2020/109506A1 |
The invention relates to compounds of formula (I) as follows: (I) wherein X1 and X2, identical or different, are NR5or a sulfur atom, Y is a group (C1-C10)alkanediyl, Ar1 and Ar2, identical or different, are an aryl group optionally subs...
|
|
WO/2020/071961A1 |
The invention relates to an agent for the targeted therapy of solid malignant tumours which contains as active ingredient dichloroacetate 1-isobutanoyl-2-isopropyl isothiourea having the structural formula shown. Said agent exhibits a co...
|
|
WO/2020/061367A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2020/047668A1 |
Provided herein are Myc-Max inhibitory compounds having the structure of Formula (I) and compositions thereof for use in the treatment of cancer. In particular, the Myc-Max inhibitory compounds may be useful for the treatment of cancers ...
|
|
WO/2020/010143A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to tre...
|
|
WO/2019/243414A1 |
The present invention relates to soluble epoxide hydrolase (sEH) inhibitors of formula (I) to processes for their obtention and to their therapeutic indications.
|
|
WO/2019/189762A1 |
Provided is a method for manufacturing a polythiol compound, including reacting thiourea having an ammonium thiocyanate content of 0.05% by mass and a polyol compound, and obtaining an isothiuronium salt.
|
|
WO/2019/179436A1 |
The present invention relates to the field of pharmaceutical chemistry. Disclosed are an acid amide compound and use thereof in the treatment of cancers. Disclosed is use of an acid amide compound represented by formula (I), or its cryst...
|
|
WO/2019/160798A1 |
Accelerator solutions containing transition metal complexes based on organic ligands having one or more S-C-N, S-C-C-N, or S-C(=S)-S moieties are useful for accelerating the peroxide cure of resins such as unsaturated polyester resins.
|
|
WO/2019/078246A1 |
Provided is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which is useful as an IDO/TDO inhibitor. The compound represented by formula (I) or a pharmaceutically acceptable salt thereof can, for exam...
|
|
WO/2018/227300A1 |
Novel urea, thiourea and squaramide compounds and bioisosteres thereof of formulas (I) and (VI) and the use thereof for treating, attenuating, inhibiting or preventing inflammation and inflammation-related pathologies are described herein.
|
|
WO/2018/219309A1 |
The present invention relates to a vinylarene derivative which modulates or inhibits the enzymatic activity of indoleamine 2,3-dioxygenase 1 (IDO-1), and the use thereof, and further relates to a vinylarene derivative and the use thereof...
|
|
WO/2018/172783A1 |
There is described a method of reducing polymer tar build-up in the production of methyl methacrylate and/or methacrylic acid by the acetone cyanohydrin process. In the method a stabiliser is contacted with the amide stage reaction mediu...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/133756A1 |
The present invention relates to a targeted autophagy agonist and an application thereof in the treatment of neurodegenerative diseases, pertaining to the technical field of pharmaceuticals for the treatment of neurodegenerative diseases...
|
|
WO/2017/168419A9 |
Disclosed methyl styrene farmin compounds, and crosslinked polymeric backbones comprising same. Further disclosed microsized and nanosized polymeric particles comprising polyisothiouronium methylstyrene (PITMS) and/or poly(methyl styrene...
|
|
WO/2018/042460A1 |
The present invention discloses sulphur functionalized polyurea composite of Formula (I) and Formula (II) that provides an insoluble solid support for effective removal of metal residues from solvent streams and other reservoirs and to t...
|
|
WO/2018/028665A1 |
Provided is a method for preparing an intermediate of 6-arylaminopyridonecarboxamide compound as an MEK inhibitor, comprising preparing a compound of formula (III) as an intermediate of 6-arylaminopyridonecarboxamide compound using a com...
|
|
WO/2017/170826A1 |
The purpose of the invention is to provide a compound useful in the prevention or treatment of diabetes, obesity, and conditions related thereto. The present invention relates to an enhancing agent for glucagon-like peptide-1 receptor ac...
|
|
WO/2017/099237A1 |
A compound represented by formula (I) and having a property of modulating the activity of an androgen receptor, or a pharmaceutically acceptable salt of the compound. X represents S or O; Z represents (Ra)n-A-(CR13R14)0-1-(CR11R12)0-1-; ...
|
|
WO/2017/096430A1 |
The present invention relates to hydroxamic acid-based compounds, their intermediates, preparation and uses. The compounds are useful in imaging, particularly for the imaging of tumours and cancer, and especially for the imaging of prost...
|
|
WO/2017/047572A1 |
A heat-sensitive recording material obtained by forming a heat-sensitive recording layer, which contains a basic dye and a developer, on a supporting body. The developer is composed of at least one N-substituted amino acid derivative rep...
|
|
WO/2016/207726A1 |
The present description provides oligourea catalysts, a polar helical oligomeric strands, and methods for catalyzing reactions with polar helical oligomeric strands and oligourea catalysts. In particular, the invention relates to a polar...
|
|
WO/2016/193284A1 |
The present invention relates to compounds of formula (I) as defined herein, to processes for preparing them, to pesticidal, in particular insecticidal, acaricidal, molluscicidal and nematicidal compositions comprising them and to method...
|
|
WO/2016/184561A1 |
Novel inhibitors of the enzyme autotaxin are described. The inhibitors contain one or two zinc-binding groups at the appropriate distance, Also described are uses thereof, such as for the inhibition of autotaxin activity and the treatmen...
|
|
WO/2016/128924A1 |
The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril. It further relates to new intermediate compounds and their use for said new c...
|
|
WO/2016/079327A1 |
The invention relates to hydrosoluble hydroxybisphosphonic derivatives of doxorubicin of formula (I) and the pharmaceutically acceptable salts thereof. The invention also relates to the use of said compounds as a drug, especially in the ...
|
|
WO/2016/062585A1 |
The present invention relates to a compound of formula (I) wherein: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and G are as defined herein; and wherein the compound of formula (I) is optionally present as an agrochemically acce...
|
|
WO/2016/040226A1 |
In its many embodiments, the present invention provides certain C-6 spirocarbocyclic iminothiadiazine compounds, including compounds Formula (I): or a tautomer thereof, and pharmaceutically acceptable salts of said compounds and said tau...
|
|
WO/2015/157242A1 |
Lysophosphatidic acid acyltransferase-beta (LPAAT-β) catalyzes the production of phosphatidic acid (PA) from lysophosphatidic acid (LPA). The lipid cofactor PA contributes to the activation of c-Raf, BRAF, mTOR and PKC-ζ. LPAAT-β expr...
|
|
WO/2015/090209A1 |
Provided in the present invention are a general formula I compound, the isomers, pharmaceutically-acceptable salt or solvate thereof, and application thereof to manufacturing medicine for preventing and/or treating drug-resistant tumours...
|
|
WO/2015/054960A1 |
Provided are a novel Lesinurad intermediate, providing a synthetic process more economical, more efficient, safer, more environmentally friendly, and suitable for large-scale industrial production for the preparation of Lesinurad. Also p...
|
|
WO/2015/030085A1 |
A photosensitive layer comprises: a phthalocyanine crystal in which a urea compound is contained. The urea compound has one or more urea moieties comprising: a carbonyl group, or a thiocarbonyl group, and two nitrogen atoms. Each of the ...
|
|
WO/2014/158654A1 |
Compounds of formula (II): wherein A, R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well...
|
|
WO/2014/143561A1 |
Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may b...
|
|
WO/2014/087431A1 |
The present invention disclose an improved one pot process for synthesis of acyl thioureas of formula (I), with yield greater than 80%, from aroyl chlorides of formula (I) wherein, R' is an aryl or a heteroarylene group substituted with ...
|
